Aditxt, Inc., a biopharmaceutical company, has been actively engaged in a series of corporate developments involving Appili Therapeutics, Inc. On April 1, 2024, Aditxt entered into an Arrangement Agreement to acquire all issued and outstanding Class A common shares of Appili through its subsidiary Adivir, Inc. The acquisition is to be completed by a statutory plan of arrangement under the Canada Business Corporation Act. Subsequent amendments to the agreement extended the outside date to November 19, 2024, and set conditions including the completion of financing by Aditxt and Appili's continuance under the Business Corporations Act (Ontario). Financial statements as of June 30, 2024, and pro forma financial information were filed to provide transparency on the financial positions of both companies. The transaction is subject to shareholder approval and the completion of financing, with a termination fee of $1.25 million applicable under certain conditions. The arrangement aims to strengthen Aditxt's position in the biopharmaceutical sector by acquiring Appili, which is dedicated to advancing the fight against infectious diseases.

Aditxt, Inc., a biopharmaceutical company, has been actively engaged in a series of corporate developments involving Appili Therapeutics, Inc. On April 1, 2024, Aditxt entered into an Arrangement Agreement to acquire all issued and outstanding Class A common shares of Appili through its subsidiary Adivir, Inc. The acquisition is to be completed by a statutory plan of arrangement under the Canada Business Corporation Act. Subsequent amendments to the agreement extended the outside date to November 19, 2024, and set conditions including the completion of financing by Aditxt and Appili's continuance under the Business Corporations Act (Ontario). Financial statements as of June 30, 2024, and pro forma financial information were filed to provide transparency on the financial positions of both companies. The transaction is subject to shareholder approval and the completion of financing, with a termination fee of $1.25 million applicable under certain conditions. The arrangement aims to strengthen Aditxt's position in the biopharmaceutical sector by acquiring Appili, which is dedicated to advancing the fight against infectious diseases.